- Home
- TYGO vs OBIO Comparison
TYGO vs OBIO Comparison
Compare TYGO & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYGO | OBIO |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.4M | 246.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TYGO | OBIO |
|---|---|---|
| Price | $3.90 | $4.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $14.25 |
| AVG Volume (30 Days) | ★ 503.1K | 194.2K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,014,000.00 | $2,638,000.00 |
| Revenue This Year | $27.36 | $36.66 |
| Revenue Next Year | $25.52 | $2.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $2.20 |
| 52 Week High | $4.50 | $5.42 |
Technical Indicators
Market Signals| Indicator | TYGO | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 60.40 |
| Support Level | $1.32 | $4.00 |
| Resistance Level | $4.41 | $5.00 |
| Average True Range (ATR) | 0.38 | 0.25 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 58.98 | 85.43 |
Price Performance
Historical ComparisonAbout TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.